Patents Assigned to MBQ Pharma
  • Heterocyclic inhibitors of Rho GTPases for the treatment of disease
    Patent number: 12673960
    Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of RhoGTPases for the treatment or prevention of cancer.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: July 7, 2026
    Assignee: MBQ Pharma
    Inventors: John Mccall, Eric Calderón-Ortiz
  • Crystalline forms of carbazole inhibitors of RhoGTPase for the treatment of disease
    Patent number: 12209078
    Abstract: Disclosed herein are crystalline forms of compounds for the inhibition of RhoGTPase. Also disclosed herein are compounds, pharmaceutical compositions, and methods of treatment of RhoGTPase-mediated diseases, such as hyperproliferative and neoplastic diseases.
    Type: Grant
    Filed: October 5, 2022
    Date of Patent: January 28, 2025
    Assignee: MBQ Pharma
    Inventors: Jocelyn M. Jiménez Cruz, Vilmalí López-Mejías, Torsten Stelzer